SC 13G: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
Published on August 6, 2003
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. )1
Sonus Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock_, $.001 par value
- --------------------------------------------------------------------------------
(Title of Class of Securities)
835692 10 4
- --------------------------------------------------------------------------------
(CUSIP Number)
July 28, 2003
- --------------------------------------------------------------------------------
Date of Event Which Requires Filing of this Statement
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
- -------------
1The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page. The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section of the Act but shall be subject to
all other provisions of the Act.
CUSIP No. 835692 10 4 Page 2 of 6 Pages
- --------------------------------------------------------------------------------
1) Name of Reporting Person Domain Public Equity Partners, L.P.
I.R.S. Identification
No. of Above Person
(Entities Only)
- --------------------------------------------------------------------------------
2) Check the Appropriate Box (a) [ ]
if a Member of a Group (b) [ ]
- --------------------------------------------------------------------------------
3) SEC Use Only
- --------------------------------------------------------------------------------
4) Citizenship or Place Delaware
of Organization
- --------------------------------------------------------------------------------
Number of 5) Sole Voting 1,425,741 shares
Shares Beneficially Power of Common Stock
Owned by Each (including shares issuable upon
Reporting Person exercise of warrants)
With
6) Shared Voting
Power -0-
--------------------------------------------------
7) Sole Disposi- 1,425,741 shares
tive Power of Common Stock
(including shares issuable upon
exercise of warrants)
--------------------------------------------------
8) Shared
Dispositive Power -0-
--------------------------------------------------
9) Aggregate Amount Beneficially 1,425,741 shares
Owned by Each Reporting person of Common Stock
(including shares issuable upon
exercise of warrants)
- --------------------------------------------------------------------------------
10) Check if the Aggregate
Amount in Row (9)
Excludes Certain Shares
- --------------------------------------------------------------------------------
11) Percent of Class
Represented by 7.9%
Amount in Row (9)
- --------------------------------------------------------------------------------
12) Type of Reporting Person PN
CUSIP No. 835692 10 4 Page 3 of 6 Pages
Schedule 13G
------------
Item 1(a) - Name of Issuer: Sonus Pharmaceuticals, Inc.
Item 1(b) - Address of Issuer's Principal Executive Offices:
22026 20th Avenue SE, Suite 102
Bothell, WA 98021
Item 2(a) - Name of Person Filing:
Domain Public Equity Partners, L.P., a Delaware
limited partnership
Item 2(b) - Address of Principal Business Office:
One Palmer Square
Princeton, NJ 08542
Item 2(c) - Place of Organization:
Delaware
Item 2(d) - Title of Class of Securities:
Common Stock, $.001 par value
Item 2(e) - CUSIP Number:
835692 10 4
Item 3 - Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b):
Not applicable.
Item 4 - Ownership.
(a) Amount Beneficially Owned:
1,425,741 shares of Common Stock (including shares
issuable upon exercise of warrants)
CUSIP No. 835692 10 4 Page 4 of 6 Pages
(b) Percent of Class:
7.9%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
1,425,741 shares of Common Stock (including shares
issuable upon exercise of warrants)
(ii) shared power to vote or to direct the vote: -0-
(iii) sole power to dispose or to direct the disposition
of:
1,425,741 shares of Common Stock (including shares
issuable upon exercise of warrants)
(iv) shared power to dispose or to direct the
disposition of: -0-
Item 5 - Ownership of Five Percent or Less of a Class:
Not applicable.
Item 6 - Ownership of More than Five Percent on Behalf of
Another Person:
Not applicable.
Item 7 - Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Company:
Not applicable.
Item 8 - Identification and Classification of Members of the Group:
Not applicable.
Item 9 - Notice of Dissolution of Group:
Not applicable.
CUSIP No. 835692 10 4 Page 5 of 6 Pages
Item 10 - Certification:
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
CUSIP No. 835692 10 4 Page 6 of 6 Pages
Signature:
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
DOMAIN PUBLIC EQUITY PARTNERS, L.P.
By: Domain Public Equity Associates, L.L.C.,
General Partner
By /s/ Nicole Vitullo
------------------------------------------
Managing Member
Date: August 6, 2003